BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal 2024, which ended March 31, 2024.

From April 17 to 26, 2024, Hesheng Wang, Vice Minister of the National Health Commission of the PRC and Director of the National Disease Control and Prevention Administration, led a delegation to visit Germany, Finland and the Republic of Korea.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the first quarter of 2024.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024.

The US Food and Drug Administration released on Monday its final rule to regulate laboratory-developed tests (LDTs).

The fully automatic biochemistry analyzer, characterized by high technical content, high accuracy, high precision, high flexibility, and high working efficiency, has become one of the indispensable instruments in the modern clinical laboratory for the increasing testing work.

Revvity's EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This collaboration brings together EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies.

The European Parliament has agreed to adopt measures to delay certain deadlines of the In Vitro Diagnostic Medical Devices Regulation (IVDR) and to gradually roll out the European Database on Medical Devices (Eudamed), the European Commission said on Thursday.

Recently, Wondfo Biotech's wholly-owned subsidiary in the United States, Wondfo USA Co., Ltd. (hereinafter referred to as the " Wondfo USA"), received notification from the U.S. Food and Drug Administration (FDA) that the WELLlife™ COVID-19/Influenza A&B Test has been granted Emergency Use Authorization (EUA240004). The WELLlife™ COVID-19/Influenza A&B Test is designed for professional use at the point-of-care (POC) settings.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq xHYB Mycobacterium tuberculosis Panel for research use, a new tool in the fight against tuberculosis (TB), the world’s leading infectious disease killer.

Chinese Aging Well Association’s Alzheimer's Disease Branch has announced the launch of a special project to establish 50 new memory clinics nationwide and to conduct training in 10 regions, aiming to train approximately 1,000 professionals.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.

Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales decline

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.